Novus Biologicals

Novus Biologicals was founded in 1996 by Karen Padgett to innovate and provide advanced solutions for all applications and areas of scientific research. Novus products are utilized in many different research areas, including autophagy, hypoxia, immunology, cancer, signal transduction, cell biology, stem cell markers, DNA repair, metabolism, cell cycle and replication, GPCR, protein kinases and apoptosis.

In 2008, Novus became a limited liability company when Mainsail Partners invested in the company. After years of significant growth in the biotechnology industry, Novus increased their brand awareness and customer base significantly. Novus Biologicals was selected by Inc. Magazine as one of the fastest-growing private companies in America 8 out of the last 12 years.[1] In 2010, Novus Biologicals was announced as one of the top 50 private companies to watch in Colorado by ColoradoBIZ.[2]

In 2013, Novus Biologicals acquired Imgenex – a first big step in building their catalog of products.[3] In 2014, antibody and reagent supplier Bio-Techne acquired Novus Biologicals for $60 million.[4] The acquisition was meant to provide scientists and doctors a broader selection of products in one location.[5] Bio-Techne has more than 30 sites worldwide and sells their products directly to customers in the biotechnology research field.[6] As of 2019, Bio-Techne has acquired over 15 companies and has over 2,200 employees across the globe.[7]